MedTrace Logo

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

NCT04821778 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2026-01-21

No results posted yet for this study

Summary

Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.

Conditions

  • Esophagus Cancer
  • Esophagogastric Junction Cancer
  • Chemoradiation
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy Effect

Interventions

RADIATION

Radiotherapy

50-66Gy/1.8-2.2Gy/25-30f

DRUG

Platinum based chemotherapy

q1-3W according to physician's preference

DRUG

Paclitaxel based chemotherapy

q1-3W according to physician's preference

DRUG

Immunotherapy

Anti-PD-1/PD-L1 Antibody

DRUG

5-FU Analog based chemotherapy

W1-5 qW or d1-14, q3W according to physician's preference

DRUG

Nimotuzumab

200-400mg, d1,qW

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04821778 on ClinicalTrials.gov